RAPT Therapeutics(US:RAPT)2021-10-01 18:38RPT193 Program (Inflammation) - RPT193 is an oral CCR4 antagonist targeting inflammatory Th2 cells, with Phase 1b trial demonstrating efficacy on key endpoints and favorable safety in Atopic Dermatitis (AD)[7, 15] - The Atopic Dermatitis (AD) market is projected to reach $24 billion by 2029, while the Asthma market is projected to reach $21 billion by 2029[20] - In the Phase 1b trial, RPT193 showed a differentiated improvement from placebo for EASI at Day 29, with further improvement at Day 43[28] - In the Phase 1b trial, 4.8% of the placebo group achieved vIGA 0/1 (Clear/Almost Clear) at Day 29, compared to 14.3% in the RPT193 group[34] - In the Phase 1b trial, 22.2% of the placebo group showed improvement in NRS-4, compared to 45% in the RPT193 group[37] - The company plans to initiate a Phase 2b trial in Atopic Dermatitis (AD) and a Phase 2a trial in Asthma[15, 44, 45] FLX475 Program (Oncology) - FLX475 selectively targets immunosuppressive tumor Treg, with Phase 2 showing monotherapy and combination activity[7, 52] - The company is evaluating FLX475 in combination with pembrolizumab in checkpoint-naïve cancers[58, 66] - The company has ungated Stage 2 expansions in EBV+ lymphoma, nasopharyngeal and head and neck cancers (CPI naïve and CPI refractory)[66]